GPRC5D-Targeted CAR T Cells for Myeloma

In an early-phase study involving 17 patients with highly refractory multiple myeloma, CAR T-cell therapy with specificity for a G protein–coupled receptor that is expressed on myeloma cells produced a response in 71% of the patients.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-09, Vol.387 (13), p.1196-1206
Hauptverfasser:	Mailankody, Sham, Devlin, Sean M., Landa, Jonathan, Nath, Karthik, Diamonte, Claudia, Carstens, Elizabeth J., Russo, Douglas, Auclair, Romany, Fitzgerald, Lisa, Cadzin, Briana, Wang, Xiuyan, Sikder, Devanjan, Senechal, Brigitte, Bermudez, Vladimir P., Purdon, Terence J., Hosszu, Kinga, McAvoy, Devin P., Farzana, Tasmin, Mead, Elena, Wilcox, Jessica A., Santomasso, Bianca D., Shah, Gunjan L., Shah, Urvi A., Korde, Neha, Lesokhin, Alexander, Tan, Carlyn R., Hultcrantz, Malin, Hassoun, Hani, Roshal, Mikhail, Sen, Filiz, Dogan, Ahmet, Landgren, Ola, Giralt, Sergio A., Park, Jae H., Usmani, Saad Z., Rivière, Isabelle, Brentjens, Renier J., Smith, Eric L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antigens Apheresis B-Cell Maturation Antigen - therapeutic use Bone marrow Cell therapy Cerebellum Chimeric antigen receptors Consent Cytokine Release Syndrome - etiology Cytokines Drug dosages Hematology Humans Immunotherapy Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Leukemia Lymphocytes Lymphocytes B Lymphocytes T Lymphoma Multiple myeloma Multiple Myeloma - drug therapy Neoplasm Recurrence, Local - etiology Neurotoxicity Oncology Patients Proteins Receptors, Chimeric Antigen - therapeutic use Receptors, G-Protein-Coupled - therapeutic use T-Lymphocytes Treatments in Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In an early-phase study involving 17 patients with highly refractory multiple myeloma, CAR T-cell therapy with specificity for a G protein–coupled receptor that is expressed on myeloma cells produced a response in 71% of the patients.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2209900